MAM
SPRO icon

Meeder Asset Management’s Spero Therapeutics SPRO Stock Holding History

Meeder Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,609
Closed -$13K – 2437
2020
Q1 		$13K Buy
1,609
+1,074
+201% +$9.47K ﹤0.01% 1411
2019
Q4 		$5K Hold
535
– – ﹤0.01% 1803
2019
Q3 		$6K Sell
535
-959
-64% -$10.1K ﹤0.01% 1713
2019
Q2 		$17K Buy
1,494
+1,185
+383% +$14.3K ﹤0.01% 1304
2019
Q1 		$4K Buy
+309
New +$3.28K ﹤0.01% 1456

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's SPRO Position: Q2 2020 in Review

Meeder Asset Management sold out of Spero Therapeutics (SPRO) in Q2 2020, closing a stake of 1,609 shares — an estimated $13K sold.

Meeder Asset Management first reported a position in SPRO in Q1 2019 and held it in 5 quarters. The position peaked at $17K in Q2 2019. 80 funds tracked by Wall St. Rank hold SPRO as of Q2 2020.

  • Meeder Asset Management reported no remaining Spero Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 1,609 Spero Therapeutics shares in Q2 2020, an estimated $13K.
  • Meeder Asset Management first reported a position in Spero Therapeutics in Q1 2019 and held it in 5 quarters.
  • Meeder Asset Management's Spero Therapeutics position peaked at $17K in Q2 2019.
  • 80 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.